{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:19:35Z","timestamp":1759033175942},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143356","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T21:50:19Z","timestamp":1448401819000},"page":"e0143356","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan"],"prefix":"10.1371","volume":"10","author":[{"given":"Norio","family":"Sugawara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Tsuchimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanako","family":"Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"J van Os","year":"2009","journal-title":"Lancet"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"R Freedman","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0278-5846(01)00218-4","article-title":"Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms","volume":"26","author":"N Yasui-Furukori","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","article-title":"Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia","volume":"53","author":"Q Rui","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","article-title":"Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options","volume":"10","author":"P Chue","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0269881111405555","article-title":"Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients","volume":"26","author":"N Yasui-Furukori","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"M DE Hert","year":"2011","journal-title":"World Psychiatry"},{"issue":"2\u20133","key":"ref8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2010.08.030","article-title":"Prevalence of metabolic syndrome among patients with schizophrenia in Japan","volume":"123","author":"N Sugawara","year":"2010","journal-title":"Schizophr Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-244X-13-108","article-title":"Body mass index and quality of life among outpatients with schizophrenia in Japan","volume":"13","author":"N Sugawara","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/NMD.0b013e318247d24f","article-title":"Ethical issues of placebo-controlled studies in depression and a randomized withdrawal trial in Japan: case study in the ethics of mental health research","volume":"200","author":"S Tashiro","year":"2012","journal-title":"J Nerv Ment Dis"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1176\/appi.ajp.160.2.356","article-title":"The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia","volume":"160","author":"WT Carpenter Jr","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"ref12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.schres.2013.09.008","article-title":"Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?","volume":"150","author":"R Emsley","year":"2013","journal-title":"Schizophr Res"},{"issue":"7","key":"ref13","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"J Busner","year":"2007","journal-title":"Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-859X-10-2","article-title":"Guidelines for rating Global Assessment of Functioning (GAF)","volume":"10","author":"IH Aas","year":"2011","journal-title":"Ann Gen Psychiatry"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4088\/JCP.v64n0308","article-title":"Attitudes of patients with schizophrenia toward placebo-controlled clinical trials","volume":"64","author":"M Hummer","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref16","article-title":"Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","year":"2013"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1176\/appi.ajp.159.4.573","article-title":"Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions","volume":"159","author":"LW Roberts","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00127-010-0181-7","article-title":"Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries","volume":"46","author":"I Sch\u00e4fer","year":"2011","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00213-002-1060-z","article-title":"Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe","volume":"162","author":"WW Fleischhacker","year":"2002","journal-title":"Psychopharmacology"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004714-200004000-00018","article-title":"Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia","volume":"20","author":"P Mohr","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","article-title":"Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs","volume":"62","author":"G Kemmler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archpsyc.60.5.458","article-title":"Placebo or active control trials of antipsychotic drugs?","volume":"60","author":"WW Fleischhacker","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"ref23","first-page":"132","article-title":"Ethical and Scientific Perspectives of Placebo-controlled Trials in Schizophrenia","volume":"1","author":"Y Melamed","year":"2009","journal-title":"J Clin Med Res"},{"issue":"6549","key":"ref24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.293.6549.726","article-title":"Does short term placebo treatment of chronic schizophrenia produce long term harm?","volume":"293","author":"DA Curson","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2\u20133","key":"ref25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"RB Zipursky","year":"2014","journal-title":"Schizophr Res"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"R Emsley","year":"2012","journal-title":"Schizophr Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:00:05Z","timestamp":1540346405000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143356"}},"subtitle":[],"editor":[{"given":"Therese","family":"van Amelsvoort","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143356","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}